Zeven (dalbavancin) / RaQualia, AbbVie - LARVOL DELTA

Dalbavancin pharmacokinetics in complicated Staphylococcus aureus bacteraemia. A secondary analysis of the DOTS randomised clinical trial (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • PK/PD data

Dalbavancin use in vascular graft infections: a report of three cases (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Dalbavancin as chronic suppressive therapy in a patient with aortic vascular prosthesis due to CA-MRSA and a severe renal failure (ESCMID Global 2026) - No abstract available

Clinical • Renal Disease

Fluorescent/dalbavancin improves imaging of implant-associated osteomyelitis (ESCMID Global 2026) - No abstract available

Inflammation

The 101 Dalbatians: a descriptive analysis of clinical features, microbiology, and outcomes of TDM-guided dalbavancin therapy in osteoarticular infections (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Long-term (> one year) suppressive therapy with dalbavancin in a tertiary care hospital (ESCMID Global 2026) - No abstract available

Clinical

Role of the WTA biosynthesis gene tarA in dalbavancin resistance in Staphylococcus aureus (ESCMID Global 2026) - No abstract available

Subinhibitory concentrations of cefadroxil delay or prevent dalbavancin resistance and alter mutational pathways in S. aureus (ESCMID Global 2026) - No abstract available

Profiling of dalbavancin resistance in clinical MRSA through a nationwide genomic survey in China: insights into resistance mechanisms (ESCMID Global 2026) - No abstract available

Clinical

Economic outcomes with dalbavancin vs standard of care in complicated Staphylococcus aureus bacteraemia: findings from the DOTS trial (ESCMID Global 2026) - No abstract available

HEOR

Off-label use of dalbavancin for osteoarticular infections and deep surgical site infections in children and adolescents: experience from a paediatric Italian tertiary care hospital (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pediatrics

Toward model informed precision dosing for Dalbavancin (ESCMID Global 2026) - No abstract available

Pharmacokinetics of dalbavancin in complicated Staphylococcus aureus bacteraemia (ESCMID Global 2026) - No abstract available

PK/PD data

Optimising dalbavancin therapy: bayesian TDM insights for extending dosing intervals (ESCMID Global 2026) - No abstract available

Optimising dalbavancin long-term therapy: a hybrid machine learning and population pharmacokinetic strategy for personalised dosing (ESCMID Global 2026) - No abstract available

Clinical • Machine learning • PK/PD data

Beyond soft tissue infections: dalbavancin as a promising option for spondylodiscitis, osteomyelitis, and implant-related infections (ESCMID Global 2026) - No abstract available

Infectious Disease • Inflammation

Clinical experience with dalbavancin for the treatment of skin and soft tissue infections in vulnerable patient populations (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

In vivo dalbavancin efficacy against two different methicillin-resistant Staphylococcus epidermidis (MRSE) strains in an experimental endocarditis model (ESCMID Global 2026) - No abstract available

Preclinical • Cardiovascular

Partial oral vs dalbavancin for outpatient treatment of infective endocarditis: experience in a reference centre (ESCMID Global 2026) - No abstract available

Clinical • Cardiovascular

Dalbavancin. (PubMed, CMAJ) - No abstract available

Journal

EFFECTIVENESS AND SAFETY OF DALBAVANCIN IN INFECTIVE ENDOCARDITIS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS (ACC 2026) - "In this meta-analysis, dalbavancin was associated with high clinical success, low relapse rates, and a favorable safety profile in patients with IE."

Retrospective data • Review • Cardiovascular

Persistent headache after dalbavancine infusion: About one case (PubMed, Therapie) - No abstract available

Journal • Pain

Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections. (PubMed, Infection) - "CorA shows strong in vitro activity against a broad range of staphylococcal strains, particularly methicillin-resistant isolates. Its additive effects with clinically relevant antibiotics further support its potential in combination therapy for the treatment of resistant staphylococcal infections."

Journal • Infectious Disease

Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. (PubMed, Open Forum Infect Dis) - "This is the first report of dalbavancin nonsusceptibly associated with an LVAD infection, but dalbavancin resistance has been documented previously in association with treatment of endovascular infections. Combination therapy with synergistic and orally bioavailable agents like cefadroxil may be a reasonable strategy to enhance activity and possibly diminish emergence of resistance to dalbavancin."

Journal • Cardiovascular • Infectious Disease

Leukocytoclastic Vasculitis Induced by Dalbavancin: A Case Report. (PubMed, Am J Case Rep) - "CONCLUSIONS To the best of our knowledge, this is the first published, histologically confirmed case report of LV developing after treatment with dalbavancin. Given the widespread use of dalbavancin for treating ABSSSIs, clinicians should be aware of the potential adverse effects, including LV, that may arise during its administration."

Journal • Infectious Disease • Musculoskeletal Pain • Vasculitis